Funding for this research was provided by:
Received: 6 March 2020
Accepted: 27 July 2020
First Online: 3 August 2020
Ethics approval and consent to participate
: The study protocol was approved by the ethics committee or institutional review board at each clinical site, and all patients provided signed informed consent before the start of any study-related procedures. The study was conducted in accordance with the International Council for Harmonisation Good Clinical Practice Guidelines and conforms to the provisions of the Declaration of Helsinki.
: Not applicable.
: JMP is a consultant/on advisory boards for Alder Biopharmaceuticals, Allergan, Amgen, Biohaven, Promius Pharma and receives research funding from NIH/NIA K23AG049466-05. KP has received personal compensation from Allergan, Amgen/Novartis, Eli Lilly, and Teva for consulting, serving on a scientific advisory board, and/or speaking and is a clinical trial investigator for Amgen/Novartis (erenumab), Eli Lilly (galcanezumab), and Autonomic Technologies Inc. (sphenopalatine ganglion stimulation). HG has received research support from Allergan, Amgen, Bayer, Novartis, Menarini, and Teva and is a speaker for Allergan, Novartis, and Teva. JB has nothing to disclose. AR is an advisor for Allergan, Amgen, Amneal, Assertio, Autonomic Technologies Inc., Biohaven, Cala Health, Neurolief, Promius, Satsuma, Teva, Theranica, Xoc, and Zosano and is on a speakers’ bureau for Amgen and Teva. RK is a consultant for Amgen. FZ is an employee of Amgen Inc. HP and DDM are employees and stockholders of Amgen.